search
Back to results

STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI) (APPOSITION ll)

Primary Purpose

STEMI

Status
Completed
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Stentys coronary stent
Balloon-expandable stent
Sponsored by
Stentys
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for STEMI focused on measuring STEMI, self-expandable, balloon-expandable

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject 18 years old.
  2. Acute Myocardial Infarction defined as presence of at least two of the three items below:

    1. Detection of rise of cardiac biomarkers with a least one value above the 99th percentile of the upper reference limit (URL)
    2. Symptoms of ischaemia (chest pain) >20 minutes
    3. ECG changes indicative of new ischaemia: new ST-T changes (ST deviation ≥0.2mV precordial leads and/or ≥0.1mV limb leads) or new LBBB)
  3. Reperfusion expected to be achieved within 12 hours from the onset of symptoms
  4. Subject understands the nature of the procedure and provides written informed consent prior to the catheterization procedure.
  5. Subject is willing to comply with specified follow-up evaluation and can be contacted by telephone.
  6. Acceptable candidate for coronary artery bypass graft (CABG) surgery.
  7. Male or non-pregnant female subject.

Angiographic Inclusion Criteria:

  1. Reference vessel diameter >2.5mm and <4.0mm by visual estimate.
  2. Target lesion <30mm in length by visual estimate

Exclusion Criteria:

  1. Currently enrolled in another investigational device or drug study that has not completed the primary endpoint or that clinically interferes with the current study endpoints.
  2. Coronary or cardiac intervention or major surgery of any kind within 30 days prior to the procedure.
  3. Target vessel supplied by by-pass vessel
  4. Patients on anticoagulation therapy (Coumadin)
  5. Patient received thrombolytic therapy.
  6. Myocardial infarction due to stent thrombosis, or infarct lesion at the side of a previously implanted stent
  7. Cardiogenic shock
  8. Any previous stent placement within 10mm (proximal or distal) of the target lesion.
  9. Co-morbid condition(s) that could limit the subject's ability to participate in the study or to comply with follow-up requirements, or impact the scientific integrity of the study.
  10. Concurrent medical condition with a life expectancy of less than 6 months.
  11. Left ventricular ejection fraction (LVEF) <30% at the most recent evaluation.
  12. Cerebrovascular accident or transient ischemic attack in the last 6 months.
  13. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, or sensitivity to contrast media, which cannot be adequately pre-medicated.
  14. Known serum creatinine level >2.5mg/dl or presence or history of renal failure

Angiographic Exclusion Criteria:

  1. Unprotected left main coronary artery disease (obstruction greater than 50% in the left main coronary artery that is not protected by at least one non-obstructed bypass graft to the left anterior descending (LAD) or left circumflex (LCX) artery or a branch thereof).
  2. Target vessel is excessively tortuous (two bends >90˚ to reach the target lesion).
  3. Lesion location that is aorto-ostial or within 5mm of the origin of the LAD or LCX.
  4. Target lesion is severely calcified.

Sites / Locations

  • C. Spaulding

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Self-expanding stent

Balloon-expandable stent

Arm Description

Stentys stent

VISION/Driver

Outcomes

Primary Outcome Measures

Stent strut apposition measured by optical coherence tomography (OCT)

Secondary Outcome Measures

Stent thrombosis

Full Information

First Posted
November 4, 2009
Last Updated
January 21, 2011
Sponsor
Stentys
search

1. Study Identification

Unique Protocol Identification Number
NCT01008085
Brief Title
STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI)
Acronym
APPOSITION ll
Official Title
Randomized Comparison Between the STENTYS Self-expanding Coronary Stent and a Balloon-expandable Stent in Acute Myocardial Infarction - APPOSITION II
Study Type
Interventional

2. Study Status

Record Verification Date
January 2011
Overall Recruitment Status
Completed
Study Start Date
November 2009 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
December 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Stentys

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Study hypothesis: the Stentys self-expandable Stent results into a better alignment of the struts to the vessel wall than a balloon-expandable stent within a few days after the procedure in acute myocardial infarction patients.
Detailed Description
Stent strut malapposition and stent underexpansion are a common phenomenon in AMI as a result of the changing anatomy after an AMI has occurred (thrombus dissolution, resolution of spasm) with the traditional balloon-expandable stent treatment. A self-expanding stent might lead to better stent strut apposition as it follows the contours of the vessel wall due to its self-expanding properties. This might result into better long term clinical outcomes like lower thrombosis rates.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
STEMI
Keywords
STEMI, self-expandable, balloon-expandable

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Self-expanding stent
Arm Type
Experimental
Arm Description
Stentys stent
Arm Title
Balloon-expandable stent
Arm Type
Active Comparator
Arm Description
VISION/Driver
Intervention Type
Device
Intervention Name(s)
Stentys coronary stent
Other Intervention Name(s)
Self-expanding stent
Intervention Description
Self-expanding Nitinol stent
Intervention Type
Device
Intervention Name(s)
Balloon-expandable stent
Other Intervention Name(s)
VISION/Driver
Intervention Description
VISION/Driver
Primary Outcome Measure Information:
Title
Stent strut apposition measured by optical coherence tomography (OCT)
Time Frame
3 days after procedure
Secondary Outcome Measure Information:
Title
Stent thrombosis
Time Frame
30 days and 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject 18 years old. Acute Myocardial Infarction defined as presence of at least two of the three items below: Detection of rise of cardiac biomarkers with a least one value above the 99th percentile of the upper reference limit (URL) Symptoms of ischaemia (chest pain) >20 minutes ECG changes indicative of new ischaemia: new ST-T changes (ST deviation ≥0.2mV precordial leads and/or ≥0.1mV limb leads) or new LBBB) Reperfusion expected to be achieved within 12 hours from the onset of symptoms Subject understands the nature of the procedure and provides written informed consent prior to the catheterization procedure. Subject is willing to comply with specified follow-up evaluation and can be contacted by telephone. Acceptable candidate for coronary artery bypass graft (CABG) surgery. Male or non-pregnant female subject. Angiographic Inclusion Criteria: Reference vessel diameter >2.5mm and <4.0mm by visual estimate. Target lesion <30mm in length by visual estimate Exclusion Criteria: Currently enrolled in another investigational device or drug study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. Coronary or cardiac intervention or major surgery of any kind within 30 days prior to the procedure. Target vessel supplied by by-pass vessel Patients on anticoagulation therapy (Coumadin) Patient received thrombolytic therapy. Myocardial infarction due to stent thrombosis, or infarct lesion at the side of a previously implanted stent Cardiogenic shock Any previous stent placement within 10mm (proximal or distal) of the target lesion. Co-morbid condition(s) that could limit the subject's ability to participate in the study or to comply with follow-up requirements, or impact the scientific integrity of the study. Concurrent medical condition with a life expectancy of less than 6 months. Left ventricular ejection fraction (LVEF) <30% at the most recent evaluation. Cerebrovascular accident or transient ischemic attack in the last 6 months. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, or sensitivity to contrast media, which cannot be adequately pre-medicated. Known serum creatinine level >2.5mg/dl or presence or history of renal failure Angiographic Exclusion Criteria: Unprotected left main coronary artery disease (obstruction greater than 50% in the left main coronary artery that is not protected by at least one non-obstructed bypass graft to the left anterior descending (LAD) or left circumflex (LCX) artery or a branch thereof). Target vessel is excessively tortuous (two bends >90˚ to reach the target lesion). Lesion location that is aorto-ostial or within 5mm of the origin of the LAD or LCX. Target lesion is severely calcified.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefan Verheye, MD, Ph.D
Organizational Affiliation
ZNA, Middelheim, Belgium
Official's Role
Principal Investigator
Facility Information:
Facility Name
C. Spaulding
City
Paris
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
26549374
Citation
Nakatani S, Onuma Y, Ishibashi Y, Karanasos A, Regar E, Garcia-Garcia HM, Tamburino C, Fajadet J, Vrolix M, Witzenbichler B, Eeckhout E, Spaulding C, Reczuch K, La Manna A, Spaargaren R, Capodanno D, Van Langenhove G, Verheye S, Serruys PW, van Geuns RJ. Incidence and potential mechanism of resolved, persistent and newly acquired malapposition three days after implantation of self-expanding or balloon-expandable stents in a STEMI population: insights from optical coherence tomography in the APPOSITION II study. EuroIntervention. 2015 Dec;11(8):885-94. doi: 10.4244/EIJY15M11_01.
Results Reference
derived
PubMed Identifier
23257368
Citation
van Geuns RJ, Tamburino C, Fajadet J, Vrolix M, Witzenbichler B, Eeckhout E, Spaulding C, Reczuch K, La Manna A, Spaargaren R, Garcia-Garcia HM, Regar E, Capodanno D, Van Langenhove G, Verheye S. Self-expanding versus balloon-expandable stents in acute myocardial infarction: results from the APPOSITION II study: self-expanding stents in ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2012 Dec;5(12):1209-19. doi: 10.1016/j.jcin.2012.08.016.
Results Reference
derived

Learn more about this trial

STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI)

We'll reach out to this number within 24 hrs